•  
  •  
  •  
  •  

2026-04-18 15:43:42

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Icon Facilitators Ltd receives order worth Rs. 1.38 crore
  • Bhooth Bangla roars at the Box Office - Smashes Rs. 21.60 crore on Day 1
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Ola Electric Announces Ola Sona Weekend with Benefits Worth up to ₹50,000 for Akshaya Tritiya
  • Hardwyn India Secures Major Orders for Newly Launched ISI-Certified Floor Springs

Keywords Selected:  UPI

Research

  • UPI transactions witnesses 118% rise at retail stores in 2023: PayNearby Report
  • UPI transactions witnesses 650% rise at rural and semi-urban stores: PayNearby
  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD
  • BFSI Sector Update - Connecting The Dots - UPI drags payments fee yields; BNPL endgame ahead
  • Views on announcements related to UPI payments in the RBI monetary policy today

IPO News

  • Robust QIB demand for Jupiter Hospital IPO, Issue subscribed 64 times
  • Jupiter Life Line Hospitals IPO subscribed 3.3 times on Day 2
  • Jupiter Life Line Hospitals IPO subscribed 87% on Day 1
  • Jupiter Life Line Hospitals Ltd's IPO to open on Sep 6, 2023, sets price band at ₹695 to ₹735 per Equity Share
  • Jupiter Life Line Hospitals gets SEBI Nod for IPO
  • Jupiter Life Line Hospitals raised Rs123 cr in pre -IPO round
  • Multispecialty Hospital Chain, Jupiter Life Line Hospitals files DRHP for IPO

Stock Report

  • USFDA inspection at Somerset facility of Lupin Ltd
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Cupid Limited Deploys ₹ 82.88 crore as Strategic Investment into Baazar Style Retail Ltd
  • Lupin Completes Acquisition of VISUfarma
  • Cupid Ltd Set to Deliver Strongest Quarter in Its History and Surpass Annual Guidance
  • Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
  • Jupiter Life Line Hospitals Ltd gets land allotment from MMRDA
  • Cupid Breweries and Distilleries Ltd acquires land in Goa
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • NPST Bags UPI Switch Mandate from Large Cooperative Bank Under Bank-in-a-Box Platform
  • Jio Payments Bank introduces UPI-based cash withdrawal services
  • Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India
  • Cupid Breweries and Distilleries Ltd inks agreement with Bansal Udyog Pvt Ltd for West Bengal foray
  • Cupid Ltd announces Strategic Branding Alignment: 'Made in India' with 'Japanese Quality'
  • Lupin Ltd gets two observations from USFDA for Ankleshwar facility
  • Lupin Receives EIR from US FDA for its Goa Facility
  • Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans
  • IndusInd Bank Goes Live with Next-Gen UPI Processing Platform
  • Lupin announces the approval and launch of Brivaracetam Oral Solution in the United States
  • Lupin receives European Commission approval for Biosimilar Ranibizumab
  • Lupin signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada

Industry News

  • UPI for Secondary Market
  • Cashfree Payments launches one-step UPI payment solution for mobile-first businesses

Latest Post

  • Icon Facilitators Ltd receives order worth Rs. 1.38 crore
  • Bhooth Bangla roars at the Box Office - Smashes Rs. 21.60 crore on Day 1
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Ola Electric Announces Ola Sona Weekend with Benefits Worth up to ₹50,000 for Akshaya Tritiya
  • Hardwyn India Secures Major Orders for Newly Launched ISI-Certified Floor Springs


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025